Search PubMed⌕ Search

Biomedical subjects

T J Priestman

Publications and source records attributed to T J Priestman.

53 records · Page 3Linked to original sources
PubMed1980

Initial evaluation of human lymphoblastoid interferon in patients with advanced malignant disease.

A study was carried out to establish the maximum tolerated dose of human lymphoblastoid interferon and to define its side effects when given by intramuscular injection. Pyrexia limited the initial dose to a maximum of 3 megaunits/m2 body surface area, but tolerance to this effect developed over 4 to 5 days and the dose was then increased to 5 to 7.5 megaunits/m2; subjective disturbance prevented further increase in dose, but 2.5 to 5.0 megaunits/m2 daily was well tolerated and appears suitable for long-term administration. Other side effects were hypertension, hypotension, myelosuppression, and disturbance of liver-function tests. All toxic effects were reversible on stopping the interferon. Two patients showed evidence of tumour regression, indicating that further trials are justified to define the extent of anticancer activity.

Adolescent↗
PubMed1976

Evaluation of quality of life in patients receiving treatment for advanced breast cancer.

Linear analogue self-assessment was used to measure the subjective effects of treatment in women with advanced breast cancer. The results show that this technique may be used to monitor the subjective benefit of treatment and to compare the subjective toxicities of different therapeutic regimens. The results also suggest that the subjective toxicity of cytotoxic therapy is not related to the patient's age and diminishes with successive courses of drugs.

Antineoplastic Agents↗
PubMed1973

Results in fifty cases of advanced squamous cell carcinoma of the head and neck treated by intravenous chemotherapy.

The results of intravenous chemotherapy for advanced squamous cell carcinoma of the head and neck in 50 patients are presented. Forty patients were treated with methotrexate alone-3 patients showed partial regression of disease and a further 7 were controlled for periods of up to 4 months. Of those patients who failed to respond, or who relapsed on methotrexate, 16 were treated with combination chemotherapy. One patient showed complete regression of disease, 2 partial regression and in 2 others control was achieved for up to 4 months. A further 10 patients were treated with combination chemotherapy only, with no previous methotrexate. In this group no objective regressions were noted and only one patient was controlled for a period of 14 months. It is suggested that intravenous chemotherapy in advanced squamous cell carcinoma of the head and neck is of doubtful value.

Adult↗
PubMed1972

Results of 27 cases with hepatic metastases treated by combination chemotherapy.

The results of using a standard combination of cytotoxic agents in 27 cases of secondary liver cancer are reported. A brief review of the methods available for treating hepatic metastases from solid tumours, as opposed to lymphomata, is included. The response rate depends on the site of the primary lesion. It is suggested that in patients with mammary or colorectal primary tumours, combination chemotherapy represents an advance in treatment with an objective response rate of 73% and 66% respectively in the 2 groups. The method requires no specialized equipment as neither grossly deranged liver enzymes nor jaundice are contra-indications to treatment, and toxicity is easily monitored and readily controlled.

Antineoplastic Agents↗
PubMedDate not supplied

A review of ondansetron in the management of radiotherapy-induced emesis.

This paper reviews experience with ondansetron in radiotherapy-induced emesis. The efficacy of ondansetron is assessed following a number of different radiotherapy regimens: single-dose radiotherapy, fractionated radiotherapy, total body irradiation (TBI) and hemi-body irradiation. In single-dose radiation-induced emesis, ondansetron (8 mg orally 3 times daily) provided superior anti-emetic control compared with metoclopramide (10 mg orally 3 times daily): 92 and 46% of patients, respectively, experienced complete control of emesis (0 emetic episodes) in the first 24 h following treatment (p < 0.001). Similarly, ondansetron (8 mg orally 3 times daily) was significantly (p < 0.001) more effective than prochlorperazine (10 mg orally 3 times daily) with 59 and 35% of patients, respectively, achieving complete control of emesis on the 'worst day' of a fractionated radiotherapy regimen (up to 20 fractions). Two studies evaluating the efficacy of ondansetron in TBI-induced emesis have demonstrated that ondansetron is effective in paediatric and adult patients receiving chemotherapy and TBI prior to bone marrow transplantation. In these studies, 57-81% of patients experienced 2 or fewer emetic episodes during TBI. For hemi-body irradiation, ondansetron (8 mg) and dexamethasone (8 mg) given orally produced complete control of emesis in 12 out of 14 patients. The effectiveness of this regimen now enables patients receiving hemi-body irradiation to be treated as outpatients in many cases. Anecdotal data also shows that ondansetron is effective when given as intervention treatment in patients with established emesis. In none of the studies were there any serious adverse events following ondansetron treatment. It can therefore be concluded that ondansetron is an effective and well tolerated antiemetic for the prophylaxis and treatment of radiation-induced emesis and nausea. The use of effective anti-emetic treatments may have resource implications such as reducing bed occupancy and enabling the use of fewer, larger fractions of radiotherapy.

Adolescent↗